Cowan Renee A, Eriksson Ane Gerda Zahl, Jaber Sara M, Zhou Qin, Iasonos Alexia, Zivanovic Oliver, Leitao Mario M, Abu-Rustum Nadeem R, Chi Dennis S, Gardner Ginger J
Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Gynecol Oncol. 2017 May;145(2):230-235. doi: 10.1016/j.ygyno.2017.02.010. Epub 2017 Mar 9.
We sought to examine compliance and outcomes using Memorial Sloan Kettering "(MSK) criteria" to predict complete gross resection (CGR) and compare them with the validated Tian and AGO models.
Patients who underwent SCS for recurrent platinum-sensitive ovarian cancer from 5/2001-6/2014 were identified. The AGO and Tian models were applied to the study population; appropriate statistical tests were used to determine ability to predict CGR.
214 SCS cases were identified. Since the implementation of MSK criteria, the CGR rate has been 86%. The AGO model had a 49% accuracy rate in predicting CGR, and predicted gross residual disease (RD) in 51%; however, CGR was achieved in 86%. The Tian model had an 88% accuracy rate. Of the 4% scored as Tian high risk for gross RD, 33% achieved a CGR. Comparing models, McNemar's p-value was 0.366 between the Tian and MSK models and <0.001 between AGO and MSK criteria. Median PFS was 21.3 (95%CI, 18.2-24.5), 22.5 (95%CI, 19.4-25.3), and 14.1months (95%CI, 9.7-22.1) for the entire cohort, for those achieving CGR, and for those left with RD, respectively (p=0.013). OS was 82.2 (95%CI, 60.2-123.3), 95.6 (95%CI, 63.6-NE), and 57.5months (95%CI, 27.5-113.9), respectively (p=0.014).
CGR during SCS is associated with extended PFS and OS. We report a high rate of CGR using MSK criteria. There was good concordance between the Tian and MSK models; however, the latter has fewer variables and is more user-friendly. Tian criteria may be applied to intermediate MSK cases for further stratification.
我们试图使用纪念斯隆凯特琳癌症中心(MSK)标准来检查依从性和结果,以预测完全肉眼切除(CGR),并将其与经过验证的田氏模型和AGO模型进行比较。
确定2001年5月至2014年6月期间因复发性铂敏感卵巢癌接受二次减瘤手术(SCS)的患者。将AGO模型和田氏模型应用于研究人群;使用适当的统计检验来确定预测CGR的能力。
共确定了214例SCS病例。自实施MSK标准以来,CGR率为86%。AGO模型预测CGR的准确率为49%,预测肉眼残留病灶(RD)的比例为51%;然而,实际CGR率为86%。田氏模型的准确率为88%。在被评为田氏高危肉眼RD的4%患者中,33%实现了CGR。比较各模型,田氏模型与MSK模型之间的McNemar p值为0.366,AGO模型与MSK标准之间的p值<0.001。整个队列、实现CGR的患者以及残留RD的患者的中位无进展生存期(PFS)分别为21.3个月(95%CI,18.2 - 24.5)、22.5个月(95%CI,19.4 - 25.3)和14.1个月(95%CI,9.7 - 22.1)(p = 0.013)。总生存期(OS)分别为82.2个月(95%CI,60.2 - 123.3)、95.6个月(95%CI,63.6 - 无上限)和57.5个月(95%CI,27.5 - 113.9)(p = 0.014)。
SCS期间的CGR与延长的PFS和OS相关。我们报告了使用MSK标准的高CGR率。田氏模型与MSK模型之间有良好的一致性;然而,后者变量更少,更便于使用。田氏标准可应用于MSK标准的中间病例进行进一步分层。